Idioma:

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

Taxonera, C. ; Estellés, J. ; Fernández‐Blanco, I. ; Merino, O. ; Marín‐Jiménez, I. ; Barreiro‐de Acosta, M. ; Saro, C. ; García‐Sánchez, V. ; Gento, E. ; Bastida, G. ; Gisbert, J. P. ; Vera, I. ; Martinez‐Montiel, P. ; Garcia‐Morán, S. ; Sánchez, M. C. ; Mendoza, J. L.

Alimentary pharmacology & therapeutics, 2011-02, Vol.33 (3), p.340-348 [Periódico revisado por pares]

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab
Autor: Taxonera, C. ; Estellés, J. ; Fernández‐Blanco, I. ; Merino, O. ; Marín‐Jiménez, I. ; Barreiro‐de Acosta, M. ; Saro, C. ; García‐Sánchez, V. ; Gento, E. ; Bastida, G. ; Gisbert, J. P. ; Vera, I. ; Martinez‐Montiel, P. ; Garcia‐Morán, S. ; Sánchez, M. C. ; Mendoza, J. L.
Assuntos: Adalimumab ; Adult ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Biological and medical sciences ; Colectomy ; Colitis, Ulcerative - drug therapy ; Colitis, Ulcerative - surgery ; Digestive system ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Infliximab ; Male ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Regression Analysis ; Retreatment ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Time Factors ; Treatment Outcome
É parte de: Alimentary pharmacology & therapeutics, 2011-02, Vol.33 (3), p.340-348
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Aliment Pharmacol Ther 2011; 33: 340–348 Summary Background The long‐term efficacy of adalimumab in patients with ulcerative colitis is not well known. Aim To evaluate the short‐ and long‐term outcomes of adalimumab in ulcerative colitis patients previously treated with infliximab. Methods Patients with active ulcerative colitis were treated with adalimumab after failure of other therapies including infliximab. Short‐term clinical response and remission were assessed at weeks 4 and 12. The proportion of patients who continued on adalimumab and the proportion of patients who remained colectomy free were assessed over the long term. Results Clinical response at weeks 4 and 12 was achieved in 16 (53%) and 18 (60%) patients, respectively, and clinical remission was obtained in 3 (10%) and 8 (27%) patients, respectively. After a mean 48 weeks’ follow‐up, 15 patients (50%) continued on adalimumab. Six patients (20%) required colectomy. All patients who achieved clinical response at week 12 were colectomy free at long term. Conclusions Adalimumab was well tolerated and induced durable clinical response in many patients with otherwise medically refractory ulcerative colitis. Patients achieving clinical response at week 12 avoided colectomy over the long term.
Editor: Oxford, UK: Blackwell Publishing Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

Taxonera, C. ; Estellés, J. ; Fernández‐Blanco, I. ; Merino, O. ; Marín‐Jiménez, I. ; Barreiro‐de Acosta, M. ; Saro, C. ; García‐Sánchez, V. ; Gento, E. ; Bastida, G. ; Gisbert, J. P. ; Vera, I. ; Martinez‐Montiel, P. ; Garcia‐Morán, S. ; Sánchez, M. C. ; Mendoza, J. L.

Oxford, UK: Blackwell Publishing Ltd

Buscando em bases de dados remotas. Favor aguardar.